Plain-English translation of NCT04939805 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a treatment called selective CRP apheresis—a procedure that filters out a substance in your blood called C-reactive protein that may worsen heart damage after a heart attack. Researchers believe that removing this substance within the first few days after you receive emergency heart treatment (called PCI) might help your heart heal better and prevent future heart problems.
After a heart attack, inflammation in the body can make heart damage worse. This medication has been shown to reduce that inflammation, and researchers want to see if removing it early can actually protect your heart and improve your long-term health.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the blood-cleaning procedure (apheresis) on days 1, 2, and 3 after your emergency heart treatment, in addition to your normal care. You will also have heart imaging scans and blood tests to measure how well your heart is recovering. The study team will follow your progress over time to see whether this treatment helps reduce the amount of permanent heart damage and improves your outcome.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Austria
Germany